The antinociceptive effect of the D 2 antagonist prochlorperazine was examined in the mouse hot-plate and abdominal constriction tests. Prochlorperazine (1-2 mg kg −1 s.c./i.p.) produced an increase of the pain threshold in the mouse hot-plate test. The antinociception produced by prochlorperazine was prevented by the D 2 selective agonist quinpirole, the unselective muscarinic antagonist atropine, the M 1 selective antagonist pirenzepine, and by the choline uptake inhibitor hemicholinium-3 hydrobromide (HC-3). Moreover, prochlorperazine antinociception was abolished by pretreatment with an aODN against the M 1 receptor subtype, administered at the dose of 2 nmol per single i.c.v. injection. By contrast the analgesic effect of prochlorperazine was not prevented by the opioid antagonist naloxone and the GABA B antagonist CGP-35348. Prochlorperazine also elicited a dose-dependent increase in ACh release from rat cerebral cortex. In the antinociceptive dose-range, prochlorperazine did not impair mouse performance evaluated by the rota-rod and hole-board tests. On the basis of the above data, it can be postulated that prochlorperazine exerted an antinociceptive effect mediated by a central cholinergic mechanism.
Introduction
Prochlorperazine is a dopamine D 2 receptor antagonist [1] clinically widely used for preventing nausea and vomiting of different origin, such as those induced by cyclophosphamide-and cisplatin-based chemotherapy [2, 3] by radiotherapy [4] or by surgery [5] [6] [7] . Prochlorperazine is also effective, after intravenous administration, in the rapid control of vomiting in the emergency department [8] . Furthermore, several antiemetic preparations contain prochlorperazine in association with granisetron, dexamethason, lorazepam, scopolamine, or nabilone [9] [10] [11] [12] . Another therapeutic use of prochlorperazine is the relief of migraine attacks. Migraine is a very common pain syndrome. It is a multifaceted disorder, of which the head pain is only one component. A migraine attack is often accompanied Abbreviations: aODN, antisense oligodeoxynucleotide; dODN, degenerate oligodeoxynucleotide; HC-3, hemicolinium-3 hydrobromide; i.c.v., intracerebroventricular; i.p., intraperitoneal; s.c., subcutaneousby nausea, vomiting, diarrhoea, photophobia, phonophobia, etc. [13] . Prochlorperazine is used, alone or in combination, in different forms of headache. In particular, positive therapeutic results were obtained in migraine attacks or tension-type and vascular headache [14] [15] [16] . Prochlorperazine is able not only to abolish nausea and vomiting, but also to relief pain occurring during a migraine attack better than metoclopramide [17] .
Prochlorperazine, therefore, is endowed with antiemetic properties. Furthermore, it seems able to exert an antialgesic activity at least in headache attacks. Taking into account these observations, the aim of the present study was to first investigate the analgesic properties of prochlorperazine in laboratory animals by using different nociceptive stimuli, such as thermal and chemical. Then, we also investigated the neurotransmitter system and receptor subtypes involved in the increase of pain threshold induced by prochlorperazine in order to elucidate its mechanism of action.
In order to exclude that the effects produced by prochlorperazine treatment were due to the induction of side effects, some additional behavioural tests, able to assess motor co-ordination (rota rod), spontaneous motility and inspection activity (hole board), were performed.
Methods

Animals
Male Swiss albino mice (23-25 g ) and Wistar rats (150-200 g) from the Morini (San Polo d'Enza, Italy) breeding farm were used. Fifteen mice or five rats were housed per cage (26 cm × 41 cm). The cages were placed in the experimental room 24 h before the test for acclimatisation. The animals were fed a standard laboratory diet and tap water ad libitum and kept at 23 ± 1 • C with a 12-h light:12-h dark cycle, light on at 07.00 a.m. All experiments were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) for experimental animal care. All efforts were made to minimise the number of animals used and their suffering.
Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was performed under ether anaesthesia, according to the method described by Haley and McCormick [18] . Briefly, during anaesthesia, mice were grasped firmly by the loose skin behind the head. A 0.4 mm external diameter, hypodermic needle attached to a 10 l syringe was inserted perpendicularly through the skull and no more than 2 mm into the brain of the mouse, where 5 l was then administered. The injection site was 1 mm to the right or left from the midpoint on a line drawn through to the anterior base of the ears. Injections were performed into the right or left ventricle randomly. To ascertain that the drugs were administered exactly into the cerebral ventricle, some mice (20%) were injected with 5 l of diluted 1:10 India ink and their brains examined macroscopically after sectioning. The accuracy of the injection technique was evaluated and the percentage of correct injections was 95.
Hot-plate test
The method adopted was described by O'Callaghan and Holtzman [19] . Mice were placed inside a stainless steel container, thermostatically set at 52.5±0.1 • C in a precision water-bath from KW Mechanical Workshop, Siena, Italy. Reaction times (s) of each animal were measured with a stop-watch before and at regular intervals up to a maximum of 60 min after treatment. The endpoint used was the licking of the fore or hind paws. Before pretreating animals, a pretest was performed: those mice scoring below 12 and over 18 s in the pretest were rejected (30%). An arbitrary cut-off time of 45 s was adopted. At least seven animals per group were used.
Abdominal constriction test
Mice were injected i.p. with a 0.6% solution of acetic acid (10 ml kg −1 ), according to Koster et al. [20] . The number of stretching movements was counted for 10 min, starting 5 min after acetic acid injection. At least 10 animals per group were used.
Hole-board test
The hole board test consisted of a 40 cm square plane with 16 flush mounted cylindrical holes (3 cm diameter) distributed 4 × 4 in an equidistant, grid-like manner. Mice were placed on the centre of the board one by one and allowed to move about freely for a period of 10 min each. Two electric eyes, crossing the plane from mid-point to mid-point of opposite sides, thus dividing the plane into four equal quadrants, automatically signalled the movement of the animal (counts in 5 min) on the surface of the plane (locomotor activity). Miniature photoelectric cells, in each of the 16 holes, recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice.
Rota-rod test
The apparatus consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-slippery surface. The rod was placed at a height of 15 cm from the base. The rod, 30 cm in length, was divided into five equal sections by six disks. Thus, up to five mice were tested simultaneously on the apparatus, with a rod-rotating speed of 16 rpm. The integrity of motor co-ordination was assessed on the basis of the number of falls from the rod in 30 s according to Vaught et al. [21] . Before pretreating animals, a pretest was performed: mice scoring less than 3 and more than six falls in the pretest were rejected (20%). The performance time was measured before (pretest) and 15, 30 and 45 min after s.c. treatment.
Antisense oligonucleotides
Low cell permeability and the high degradation of natural phosphodiester oligomers are considerable drawbacks in the application of aODNs both in vitro and in vivo. To overcome these drawbacks, phosphorothioate-capped phosphorodiester oligonucleotides were used. The above-mentioned compounds are a class of ODN derivatives shown to maintain more stable and effective concentrations in the brain when compared with their unmodified counterpart [22] . Phosphodiester oligonucleotides (ODNs) protected by terminal phosphorothioate double substitution (capped ODNs) against possible exonuclease-mediated degradation were purchased from Genosys (Cambridge, England, UK) and purified by high-performance liquid chromatography (HPLC). The 18-mer antisense ODN (aODN) 5 -CXAXC TGA GGT GTT CAT TXGXC-3 (X: phosphorothioate residues) complementary to the residues 112-129 of the published mouse M 1 cDNA sequence [23] and the 18-mer fully degenerated ODN (dODN) 5 NNN NNN NNN NNN NNN-3 (where N is G, or C, or A, or T and phosphorothioate residues are underlined) were vehiculated intracellularly by an artificial cationic lipid (DOTAP, Boehringer-Mannheim, Germany) to enhance both uptake and stability. aODN or dODN (100-400 M) were preincubated at 37 • C for 30 min with 13 M DOTAP, sterilised through a 0.2 m filter and supplied to mice by i.c.v. injection of a 5 l solution as described in the next section.
The accession number of the cDNA sequence for the mouse muscarinic receptor subtype reported in this paper (M 1 ) is J04192.
Determination of ACh release by cerebral microdialysis
Microdialysis was performed in rat parietal cortex according to Giovannini et al. [24] . The co-ordinates used for the implantation of the microdialysis tubing (AN 69 membrane, molecular weight cut off >15 kDa, Dasco, Italy) were AP 0.5 mm and H 2.3 mm from the bregma [25] . One day after surgery the microdialysis tubing was perfused at a constant flow rate (2 l min −1 ) with Ringer solution (NaCl 147, KCl 4.0, CaCl 2 1.2 mM) containing 7 M physostigmine sulphate. After a 1 h settling period the perfusate was collected at 15 min intervals in test tubes containing 5 l of 0.5 mM HCl to prevent ACh hydrolysis. The samples were then assayed for ACh content either immediately or after freezing. ACh was detected and quantified by HPLC with an electrochemical detector, as described by Damsma et al. [26] and Giovannini et al. [27] .
Drugs
The following drugs were used: morphine hydrochloride (S.A.L.A.R.); hemicholinium-3 hydrobromide (HC-3), pirenzepine dihydrochloride, naloxone hydrochloride, (−)-quinpirole, hydrochloride (RBI); atropine sulphate, prochlorperazine dimaleate, amitriptyline hydrochloride, (±)-baclofen, DOTAP (Sigma); CGP-35348 (Ciba Geigy); d-amphetamine hydrochloride (De Angeli). All drugs were dissolved in isotonic (NaCl 0.9%) saline solution immediately before use. Drug concentrations were prepared in such a way that the necessary dose could be administered in a volume of 10 ml kg −1 by s.c. or i.p. injection or 5 l per mouse by i.c.v. injection.
Statistical analysis
All experimental results are given as the mean ± S.E.M. ANOVA, followed by Fisher's Protected Least Significant Difference (PLSD) procedure for post hoc comparison, was used to verify significance between two means. Data were analysed with the StatView software for the Macintosh (1992) . P values of less than 0.05 were considered significant. 
Results
Antinociceptive activity of prochlorperazine
Prochlorperazine, as shown in Fig. 1 , increased the pain threshold in the mouse hot-plate test after i.p. administration (1-2 mg kg −1 ) whereas the dose of 0.3 mg kg −1 i.p. was devoid of any effect. Prochlorperazine was able to induce antinociception also in the mouse abdominal constriction test. At the dose of 1 mg kg −1 s.c., prochlorperazine induced antinociception of intensity comparable to that exerted by well known analgesic drugs such as morphine (1 mg kg −1 s.c.), and amitriptyline (5 mg kg −1 s.c.) (Fig. 2) . A dose 10-time lower of prochlorperazine as well as the above-mentioned reference compounds, was devoid of any effect (Fig. 2) .
Antagonism of prochlorperazine antinociception
In the mouse hot-plate test, the antinociceptive effect of prochlorperazine (2 mg kg −1 i.p.) was antagonized by the unselective muscarinic antagonist atropine (5 mg kg −1 i.p.), the selective M 1 muscarinic antagonist pirenzepine (0.1 g per mouse i.c.v.), the choline uptake inhibitor HC-3 (1 g per mouse i.c.v.) and the D 2 agonist quinpirole (0.5 g per mouse i.c.v.) (Table 1) . Otherwise, the opioid antagonist naloxone (1 mg kg −1 i.p.) and the GABA B antagonist CGP-35348 (100 mg kg −1 i.p.) were unable to prevent prochlorperazine antinociception (Table 1 ). The minimal dose of quinpirole able to prevent prochlorperazine antinociception was 0.5 g per mouse i.c.v., a concentration unable to modify morphine (7 mg kg −1 s.c.) and the GABA B agonist baclofen (4 mg kg −1 i.p.)-induced antinociception. By contrast, the dose of 0.1 g per mouse i.c.v. of quinpirole was ineffective (Fig. 3) .
All antagonists were injected 15 min before the test, with the exception of HC-3 injected 5 h before the test.
Pretreatment with a single (2 nmol per mouse i.c.v.) injection of antisense ODN (aODN) to M 1 gene on days 1, 4 and 7, prevented prochlorperazine-induced increase of pain threshold in the mouse hot-plate 24 h after the last i.c.v. injection (Fig. 4) . This antagonistic effect was not detected in the dODN-treated group, used as control ODN (Fig. 4) . Forty-eight hours after the end of the treatment, a partial reversion of prochlorperazine antinociception was detected, whereas after 96 h, prochlorperazine induced an antinoci- ceptive effect of the same intensity in aODN-, dODN-and vehicle-treated mice indicating the loss of antagonistic activity by the anti-M 1 aODN (Fig. 4) . The aODN pretreatment (2.0 nmol per i.c.v. injection) did not reduce the pain threshold in mice showing a lack of any hyperalgesic effect (Fig. 4) . The pretreatment with the dODN did not modify prochlorperazine-induced antinociception in comparison with mice injected with vehicle as shown in Fig. 4. 
Effect of prochlorperazine on cerebral ACh levels
As shown in Fig. 5 , prochlorperazine (2 mg kg −1 i.p.) significantly increased the ACh release from cerebral cortex Fig. 3 . Effect of quinpirole on prochlorperazine-induced antinociception in mouse hot-plate test. Quinpirole was administered 5 min before the other drugs. Nociceptive response was recorded 15 min after prochlorperazine (2 mg kg −1 i.p.) and 30 min after morphine (7 mg kg −1 i.p.) and baclofen (4 mg kg −1 s.c.) injection. Number of mice is reported inside the columns. * P < 0.01 vs. saline-treated mice.
• P < 0.01 vs. prochlorperazine-treated mice.
of freely moving rats. The prochlorperazine curve represents the time-course of the increase expressed as percentage change from the means of the three collection periods before prochlorperazine administration, taken as control. Prochlorperazine ACh release peaked 30 min after administration and returned to basal values within 120 min. 
Effect of prochlorperazine on mouse behaviour
The spontaneous motility and exploratory behaviour of mice was not modified by treatment with prochlorperazine (2-3 mg kg −1 i.p.) as revealed by the hole-board test (Fig.  6 ). In the same experimental conditions d-amphetamine (2 mg kg −1 s.c.), used as the reference drug, increased both parameters evaluated.
The motor co-ordination of mice treated with prochlorperazine was evaluated by using the rota-rod test (Fig. 7) . The rota-rod performance of mice treated with prochlorperazine at the dose of 1-2 mg kg −1 i.p. was not impaired in comparison with controls as indicated by a progressive reduction of the number of falls. The number of falls by control animals progressively decreased at every measurement since the mice learnt how to balance on the rotating rod. By contrast, no reduction of the number of falls was observed after administration of prochlorperazine at the dose of 3 mg kg −1 i.p. indicating the induction of motor incoordination (Fig. 7) .
Discussion
Prochlorperazine was showed to be able to induce antinociception in mice. Antinociception was elicited regardless of which noxious stimulus was used: thermal (hot-plate test) and chemical (abdominal constriction test). Prochlorperazine antinociception was obtained without producing changes of animals' gross behaviour. Moreover, prochlorperazine-treated mice showed a complete integrity of motor co-ordination on the rota-rod test, normal sponta- neous motility, as well as exploratory behaviour as revealed by the hole-board test. The antinociceptive effect of prochlorperazine appears to be due to the antagonism of D 2 receptors since the increase of the pain threshold induced by the investigated compound was prevented by pretreatment with the D 2 agonist quinpirole. Present data extend and support previous results in which the capability of D 2 antagonists to induce analgesia was suggested. Sulpiride was able to exert a potentiating effect of morphine analgesia in diabetic mice [28] and the D 2 blocker risperidone induced a potent increase of the pain threshold in the mouse tail flick test [29] . Furthermore, present results indicate that prochlorperazine antinociception is dependent on central cholinergic activation. It should be noted that several D 2 antagonists, such as sulpiride, pipotiazine and domperidone, increase K + evoked ACh release [30] , whereas the D 2 agonist quinpirole inhibit ACh efflux [31, 32] from rat striatal preparations. The increase of the pain threshold induced by the investigated compound was prevented by the non-selective muscarinic antagonist atropine, the selective M 1 -antagonist pirenzepine, the ACh depletor HC-3 and an aODN to the M 1 receptor subtype. The aODN treatment induces a transient prevention of muscarinic antinociception since the inhibition of prochlorperazine effect disappeared 96 h after the last i.c.v. injection of the aODN. This return to normal sensitivity to analgesic treatments implies both the total reversal of aODN-induced specific inhibition of M 1 gene expression and a lack of damage or toxicity associated with aODN treatment.
Cholinergic antinociception in mice is mediated by M 1 receptor stimulation. By using selective and unselective muscarinic agonists and antagonists, the involvement of M 1 receptors in muscarinic analgesia was evidenced [33, 34] . Furthermore, cholinergic antinociception induced both directly, through muscarinic agonists, and indirectly, by enhancing ACh extracellular levels through cholinesterase inhibitors, is prevented by i.c.v. administration of an antisense to the M 1 gene coding for the mouse M 1 receptor [35] .
Taking into account that HC-3 and pirenzepine were able to antagonise prochlorperazine antinociception after i.c.v. injection, this indicates that the analgesic site of action of the investigated compound is localised in the CNS.
A presynaptic mechanism facilitating cholinergic transmission is involved in prochlorperazine antinociception as revealed by the antagonism by HC-3 postsynaptic mechanism of action can be ruled out since, as reported by Bartolini et al. [33, 36] , HC-3 was not able to antagonise antinociception induced by agonists of postsynaptic muscarinic receptors such as oxotremorine, McN-A-343 and AF-102B. The hypothesis of a presynaptic cholinergic mechanism for prochlorperazine is further supported by microdialysis studies, in which an increase in ACh release from rat cerebral cortex was induced by prochlorperazine administration. This effect occurred at the same doses (2 mg kg −1 i.p.) in which the investigated D 2 antagonist exerted its antinociceptive activity. The observed facilitation of the cholinergic transmission induced by prochlorperazine appears to be a consequence of a blockade of D 2 receptors.
Other neurotransmission systems able to modulate pain threshold, such as opioid and GABAergic, are not involved in prochlorperazine antinociception since the opioid antagonist naloxone and the GABA B antagonist CGP-35348 were unable to prevent the effect of prochlorperazine. The doses and administration schedules of the above-mentioned drugs were ideal for preventing antinociception induced respectively by morphine and the GABA B agonist baclofen.
In summary, our results have shown that prochlorperazine is able to produce antinociception without inducing behavioural side effects, by potentiating endogenous cholinergic activity through antagonism of D 2 receptors.
